Clinical Trial

Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

Name: Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer — clinical trial record (NCT06734182)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: neovision

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a prospective, single-arm, multi-center, phase II clinical study to evaluate the efficacy and safety of Envafolimab injection (PD-L1) combined with Disitamab Vedotin (HER2 ADC) and Carboplatin for resectable, HER2-Mutant, stage II-IIIB, NSCLC.

Trial Details

NCT Number	NCT06734182
Lead Sponsor	Guangdong Provincial People's Hospital
Conditions	Non-small Cell Lung Cancer
Enrollment	25 participants
Start Date	2024-06-22
Primary Completion	2027-06-22 (estimated)
Study Completion	2028-06-22 (estimated)
Updated on ClinicalTrials.gov	2024-12-16